Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05782335 · ClinicalTrials.gov registry record

Analysis of T and B Cell Repertoire Changes in Response to Orencia® (Abatacept) in Rheumatoid Arthritis

A clinical trial of Rheumatoid Arthritis, sponsored by Hospital for Special Surgery, New York.

Recruiting
Registry status
72
Enrollment target
1
Study location

NCT05782335 is a study of Rheumatoid Arthritis that is actively recruiting participants, run by Hospital for Special Surgery, New York. The registered enrollment target is 72 participants, below the 4,690-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05782335, a study of Rheumatoid Arthritis, is actively recruiting participants, sponsored by Hospital for Special Surgery, New York.

RECRUITING
Registry status
72 participants
Enrollment target
1
Study location

Study Summary

The condition that will be studied is Rheumatoid Arthritis (RA), and in particular, RA patients with moderate to highly active disease who were prescribed Abatacept (Orencia®) (ABA) by their physician during their setting of care at Hospital for Special Surgery (HSS). This investigator-initiated, prospective, comparative, 3-arm observational study will examine changes in lymphocytes in RA patients starting abatacept compared to RA patients starting TNF inhibitors and to healthy controls. This will help investigators to learn more about the processes that cause joints to swell and hurt. This may also offer clues that might predict which patients will have a good or poor response to these treatments.

Conditions Studied

Study Locations (1)

New York

  • Hospital for Special Surgery - New York

Trial Details

FieldValue
Enrollment Target 72 participants
Start Date 2022-11-01
Est. Completion 2026-12

What the Registry Record Tells You About NCT05782335

The ClinicalTrials.gov registry entry for NCT05782335 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,690-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (98% lower). The listed sponsor is Hospital for Special Surgery, New York, which has 194 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Rheumatoid Arthritis appearing as the primary indexed condition, and to 0 interventions.

NCT05782335 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT05782335 about?

NCT05782335 is a clinical study titled "Analysis of T and B Cell Repertoire Changes in Response to Orencia® (Abatacept) in Rheumatoid Arthritis". The condition that will be studied is Rheumatoid Arthritis (RA), and in particular, RA patients with moderate to highly active disease who were prescribed Abatacept (Orencia®) (ABA) by their physician during their setting of care at Hospital for Special Surgery (HSS). This investigator-initiated, pr...

What is the current status of trial NCT05782335?

This trial is currently recruiting. The enrollment target is 72 participants. The study started on 2022-11-01. Estimated completion is 2026-12.

What conditions does trial NCT05782335 study?

This clinical trial studies the following conditions: Rheumatoid Arthritis.

Who is sponsoring clinical trial NCT05782335?

This trial is sponsored by Hospital for Special Surgery, New York, which has 194 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05782335 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Rheumatoid Arthritis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.